文献速递白血病

急性髓系白血病的T细胞免疫治疗:现状与未来发展

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
PubMed 文献 · Leukemia · 2021-05-05

本文综述了以T细胞为基础的免疫治疗在急性髓系白血病(AML)中的应用现状与未来方向。文章讨论了靶向CD33、CD123、CLL-1等的双特异性及双抗原受体靶向抗体、嵌合抗原受体(CAR)T细胞疗法,以及靶向PD-1、PD-L1、CTLA-4、TIM3和STING等靶点的免疫检查点抑制剂,这些疗法处于不同的临床前和临床开发阶段。

要点

  • AML的T细胞免疫治疗包括双特异性抗体、CAR-T和免疫检查点抑制剂。
  • 双特异性抗体靶点包括CD33、CD123、CLL-1等。
  • 免疫检查点抑制剂靶点包括PD-1、PD-L1、CTLA-4、TIM3和STING。

核心结论

  • 以T细胞为基础的免疫治疗是AML治疗领域正在发展的重要方向,多种疗法处于不同阶段的开发中。

研究设计与样本

  • 本文为综述,讨论了T细胞免疫治疗在AML中的现状和未来方向。

主要发现

  • 双特异性和双抗原受体靶向抗体靶向CD33、CD123、CLL-1等。
  • CAR T细胞疗法是T细胞免疫治疗的一种。
  • 免疫检查点抑制剂靶向PD-1、PD-L1、CTLA-4以及TIM3和STING等较新靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of molecular alterations, and as such, long-term disease control requires multiple therapeutic approaches. Driven largely by an improved understanding and targeting of these molecular aberrations, AML treatment has rapidly evolved over the last 3-5 years. The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML. Several immunotherapies that harness T cells against AML are in various stages of preclinical and clinical development. These include bispecific and dual antigen receptor-targeting antibodies (targeted to CD33, CD123, CLL-1, and others), chimeric antigen receptor (CAR) T-cell therapies, and T-cell immune checkpoint inhibitors (including those targeting PD-1, PD-L1, CTLA-4, and newer targets such as TIM3 and STING). The current and future directions of these T-cell-based immunotherapies in the treatment landscape of AML are discussed in this review.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Daver N, Alotaibi AS, Bücklein V, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021. PMID: 33953290. doi:10.1038/s41375-021-01253-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。